47E-CAR-T cells

47E-CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy developed at Stanford University School of Medicine for the treatment of solid tumors. These T-cells are engineered to target the CD47 antigen, a 'don't eat me' signal frequently overexpressed by cancer cells to evade macrophage-mediated phagocytosis. A unique feature of this therapy is the co-expression of an engineered CD47 variant called 47E (containing a Q31P mutation) on the surface of the CAR-T cells. This variant maintains the ability to bind SIRPα on macrophages, thereby protecting the CAR-T cells from being engulfed (fratricide). Crucially, the 47E variant is designed to be resistant to therapeutic anti-CD47 blocking antibodies. This allows for a synergistic combination therapy where co-administered anti-CD47 antibodies can promote the clearance of tumor cells (which express wild-type CD47) while the 47E-CAR-T cells remain protected and active within the tumor microenvironment. This dual approach harnesses both the adaptive (T-cell) and innate (macrophage) immune systems to enhance antitumor efficacy.

Other names

CD47(Q31P)-CAR-T cellsCD47-CAR-T cell therapyCD-47-CAR-T cell therapyCD 47-CAR-T cell therapy47E-engineered CAR-T cells